Valeant's outgoing boss Michael Pearson subpoenaed to testify before US Senate
The outgoing chief executive of under-siege Canadian drugmaker Valeant Pharmaceuticals (VRX.TO) will be grilled by a US Senate panel over rising drug prices.
Michael Pearson has been summoned to testify at a Senate Special Committee on Aging Hearing on April 27, the panel said on Monday. He will face questions on the practice of buying the rights to old medicines and increasing prices, in what will be the third time the panel has met to discuss the issue.
The Committee, which has focused primarily on the practices of Valeant and US firm Turing Pharmaceuticals under its former chief executive Martin Shkreli, has previously heard that these price hikes can severely affect patients and lead to supply problems.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze